Cidara Therapeutics to Participate in November Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. AVGO
7. SPCX
8. DE
9. OSIS
10. REAX

Get Alerts CDTX Hot Sheet

Price: $221.38 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences.

Details are as follows:

Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 11, 2025
Time: 8:00 AM ET
Format: Fireside Chat

Event: Jefferies London Healthcare Conference
Date: November 17, 2025
Time: 4:30 PM GMT
Format: Presentation

The live webcast for the events can be accessed in the Investors section on the Company’s website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days.

Cidara will also participate in one-on-one investor meetings during the conferences.

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
[email protected]